Статья
Атеросклероз и остеопороз. Общие мишени для влияния сердечно-сосудистых и антиостеопорозных препаратов (Часть II). Влияние антиостеопорозных препаратов на состояние сосудистой стенки
Во второй части обзора литературы приводятся данные о возможном влиянии антиостеопорозной терапии на сосудистую стенку и развитие кальцификации. Открытие общих биологических веществ, участвующих в развитии атеросклероза, кальцификации сосудистой стенки и остеопороза привлекает внимание ученых с точки зрения мишеней для оценки эффектов уже известных препаратов или разработки новых лекарственных средств, способных одновременно предотвратить развитие или замедлить прогрессирование как атеросклероза, так и остеопороза. В настоящее время различные группы препаратов для лечения остеопороза исследованы с целью предотвращения или снижения прогрессирования субклинического атеросклероза и сосудистой кальцификации. Изучались как антирезорбтивные препараты (бисфосфонаты, моноклональные антитела к RANKL, селективные модуляторы эстрогенных рецепторов), так и костно-анаболическая терапия, к которой относится терипаратид. Однако таких исследований немного, и наиболее перспективными препаратами, оказывающими профилактический эффект на ранних стадиях атеросклеротического повреждения, являются бисфосфонаты. У других классов антиостеопорозных препаратов не было выявлено позитивного влияния на сосудистую стенку, а некоторые из них повышали сердечно-сосудистый риск. Обращают на себя внимание расхождения в результатах экспериментальных и клинических исследований. Если в эксперименте практически все препараты для лечения остеопороза оказывали атеропротективный эффект и подавляли сосудистую кальцификацию, то в клинических условиях только бисфосфонаты подтвердили позитивное влияние на сосудистую стенку.
1. Osako M.K., Nakagami H., Koibuchi N., et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010;107(4):466-75. DOI: 10.1161/circresaha.110.216846.
2. Kanis J.A., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44. DOI:10.1007/s00198-018-4704-5.
3. Frith J.C., Mönkkönen J., Blackburn G., et al. Clodronate and liposome-encapsulated clodronate are metabolized to atoxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-67. DOI:10.1359/jbmr.1997.12.9.1358.
4. Ridley A.J., Hall A. The small GTP-binding protein who regulates the assembly of focal adhesions and actin stress fiber s in response to growth factors. Cell. 1992; 70(3):389-99.
5. van Beek E., Pieterman E., Cohen L., et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999;264(1):108-11. DOI:10.1006/bbrc.1999.1499.
6. Bevilacqua M., Dominguez L.J., Rosini S., Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14(9):773-9. DOI:10.1191/0961203305lu2219oa.
7. Danenberg H.D., Golomb G., Groothuis A., et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003;108(22):2798-804. DOI: 10.1161/01.CIR.0000097002.69209.CD.
8. Wu L., Zhu L., Shi W.H., et al. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol. 2009;602(1):124-31. DOI:10.1016/j.ejphar.2008.10.043.
9. Zhao Z., Shen W., Zhu H., et al. Zoledronate inhibits fibroblasts proliferation and activation via targeting TGF-β signaling pathway. Drug Des Devel Ther. 2018;12:3021-31. DOI:10.2147/DDDT.S168897.
10. Izutani H., Miyagawa S., Shirakura R., et al. Recipient macrophage deletion reduces the severity of graft coronary arteriosclerosis in the rat transplantation model. Transplant Proc. 1997;29:861-2.
11. Myers D.T., Karvelis K.C. Incidental detection of calcified dialysis graft on Tc-99m MDP bone scan. Clin Nucl Med. 1998;23(3):173-4.
12. Ylitalo R., Kalliovalkama J., Wu X., et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 1998;83:125-31.
13. Koshiyama H., Nakamura Y., Tanaka S., et al. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2000;85:2793-6. DOI:10.1210/jcem.85.8.6748.
14. Celiloglu M., AydinY., Balci P., et al. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with post-menopausal osteoporosis. Menopause. 2009;16(4):689-93. DOI:10.1097/gme.0b013e318194cafd.
15. Delibasi T., Emral R., Erdogan M.F., et al. Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther. 2007;24(2):319-25. DOI:10.1007/BF02849900.
16. Gonnelli S., Caffarelli C., Tanzilli L., et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27-32. DOI:10.1016/j.bone.2013.12.017.
17. Luckish A., Cernes R., Boaz M., et al. Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. Bone. 2008;43(2):279-283. DOI:10.1016/j.bone.2008.03.030.
18. Ariyoshi T., Eishi K., Sakamoto I., et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006;26(4):215-222. DOI:10.2165/00044011-200626040-00006.
19. Hashiba H., Aizawa S., Tamura K., Kogo H. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial. 2006;10(1):59-64. DOI:10.1111/j.1744-9987.2006.00345.x.
20. Okamoto M., Yamanaka S., Yoshimoto W., Shigematsu T. Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant. 2014;2014:269613. DOI:10.1155/2014/269613.
21. Torregrosa J.V., Fuster D., Gentil M.A., et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation. 2010;89(12):1476-81. DOI:10.1155/2014/269613.
22. Hill J.A., Goldin J.G., Gjertson D., et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol. 2002;9(10):1148-52.
23. Tanko L.B., Qin G., Alexandersen P., et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int. 2005;16:184-90. DOI:10.1007/s00198-004-1662-x.
24. Elmariah S., Delaney J.A., O'Brien K.D., et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women. MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56(21):1752-9. DOI:10.1016/j.jacc.2010.05.050.
25. Moen M.D., Keam S.J. Denosumab: A review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82. DOI: 10.2165/11203300-000000000-00000.
26. Cummings S.R., San Martin J., McClung M.R., et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med. 2009;20;361(8):756-65. DOI:10.1056/NEJMoa0809493.
27. Lerman D.A, Prasad S.1., Alotti N. Denosumab could be a potential inhibitor of valvular interstitial cells calcification in vitro. Int J Cardiovasc Res. 2016;5(1). DOI:10.4172/2324-8602.1000249.
28. Helas S., Goettsch C., Schoppet M., et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009;175(2):473-8. DOI:10.2353/ajpath.2009.080957.
29. Samelson E.J., Miller P.D., Christiansen C., et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450-7. DOI:10.1002/jbmr.2043.
30. University of Edinburg. Study Investigating the effect of drugs used to treat osteoporosis on progression of calcific aortic stenosis SALTIERE II. 2014. Available from: http://clinicaltrials.gov/ct2/show/NOTO2132026.
31. Guo J., Liu M., Yang D. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010;11(2):161-71. DOI:10.1016/j.cmet. 2009.12.007.
32. Robling A.G., Kedlaya R., Ellis S.N., et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelop-specific attenuation of skeletal effects in SOST-deficient mice. Endocrinology. 2011;152(8):2963-75. DOI:10.1210/en.2011-0049.
33. Rhee Y., Allen M.R., Condon K., et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011;26(5):1035-46. DOI:10.1002/jbmr.304.
34. McClung M.R., Martin J.S., Miller P.D., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med, 2005;165Z:1762-8. DOI:10.1001/archinte.165.15.1762.
35. Saag K.G., Shane E., Boonen S. et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. Engl J Med. 2007;357:2028-39 DOI:10.1056/NEJMoa07140.
36. Shao J.S., Cheng S.L., Charlton-Kachigian N. Teriparatideinhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278:50195-202. DOI:10.1074/jbc.M308825200.
37. Celer O., Akalın A., Oztunali C., Effect of teriparatide treatment on endothelial function, glucose metabolism and inflammation markers in patients with postmenopausal osteoporosis. J Clin Endocrinol. 2016;85(4):556-60. DOI:10.1111/cen.13139.
38. Yoda M., Imanishi Y., Nagata Y. et al. Teriparatide therapy reduces serum phosphate and intimamedia thickness at the carotid wall artery in patients with osteoporosis. Calcif Tissue Int. 2015l;97(1):32-9. DOI:10.1007/s00223-015-0007-4.
39. Passeri E., Mazzaccaro D., Sansoni V., et al. Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study. Int J Immunopathol Pharmacol. 2019;33:2058738418822439. DOI:10.1177/2058738418822439.
40. Cheng X.W., Kikuchi R., Ishii H., et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis. 2013;228(1):211-6. DOI:10.1016/j.atherosclerosis. 2013.01.004.
41. Zhao H., Qin X., Wang S., et al. Increased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability. Exp Ther Med. 2017;14(4):3471-6. DOI:10.3892/etm.2017.4935.
42. Li X., Li Y., Jin J., et al. Increased Serum Cathepsin K in Patients with Coronary Artery Disease. Yonsei Med J. 2014;55(4):912-9. DOI:10.3349/ymj.2014.55.4.912.
43. Samokhin A.O., Wong A., Saftig P., Bromme D. Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis. 2008;200(1):58-68. DOI:10.1016/j.atherosclerosis.2007.12.047.
44. Wu H., Du Q., Dai Q., Ge J., Cheng X. Cysteine protease cathepsins in atherosclerotic cardiovascular diseases. J Atheroscler Thromb. 2018;25(2):111-23. DOI:10.5551/jat.RV17016.
45. Stroup G., Kumar S., Jerome C. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcified Tissue International. 2009;85(4):344-55. DOI:10.1007/s00223-009-9279-x.
46. Jerome C., Missbach M., Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2011;22:3001-11. DOI:10.1007/s00198-011-1529-x.
47. Masarachia P., Pennypacker B., Pickarski M., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2011;27:509-23. DOI:10.1002/jbmr.1475.
48. Podgorski I. Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem. 2009;1:21-34.
49. Zerbini C.A., McClung M.R. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Ther Adv Musculoskelet Dis. 2013;5(4):199-209. DOI:10.1177/1759720X13490860.
50. Nakamura T., Shiraki M., Fukunaga M., et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study. Osteoporos Int. 2014;25(1):367-76. DOI:10.1007/s00198-013-2398-2.
51. Langdahl B., Binkley N., Bone H., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251-8. DOI:10.1002/jbmr.1695.
52. Bone H.G., Dempster D.W., Eisman J.A., et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015;26(2):699-712. DOI:10.1007/s00198-014-2944-6.
53. Ettinger B., Black D.M., Mitlak B.H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.
54. Kanis J.A., Johansson H., Oden A., Mc Closkey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44(6):1049-54. DOI:10.1016/j.bone.2009.02.014.
55. Clarkson T.B., Ethun K.F., Chen H., et al. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys. Menopause. 2013;20(3):274-81. DOI:10.1097/GME.0b013e318271e59b.
56. Komm BS, Thompson JR, Mirkin S. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric. 2015;18(4):503-11. DOI:10.3109/13697137.2014.992011.